Lineage Cell Therapeutics, Inc. Fair Value Adjustment of Warrants
Lineage Cell Therapeutics, Inc. (LCTX) reported Fair Value Adjustment of Warrants of -$9.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$9.44M, a 174.12% decline year-over-year.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$2.32M.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$1.26M.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $26.56M.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for fiscal 2025 was $35.73M.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for fiscal 2024 was -$2.13M.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for fiscal 2023 was $0.00.
- Lineage Cell Therapeutics, Inc. fair value adjustment of warrants for fiscal 2022 was -$225.00K.
| Period end | Fair Value Adjustment of Warrants 1 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.44M 10-Q · filed 2026-08-06 | -$11.77M 10-Q · filed 2026-08-06 | -$13.03M derived: sum of 3 quarters · filed 2026-08-06 | $13.53M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$2.32M 10-Q · filed 2026-05-12 | -$3.59M derived: sum of 2 quarters · filed 2026-05-12 | $22.97M derived: sum of 3 quarters · filed 2026-05-12 | $35.71M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $25.29M derived: sum of 2 quarters · filed 2026-03-05 | $38.03M derived: sum of 3 quarters · filed 2026-08-06 | $35.73M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $26.56M 10-Q · filed 2025-11-06 | $39.30M derived: sum of 2 quarters · filed 2026-08-06 | $36.99M 10-Q · filed 2025-11-06 | $34.86M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $12.74M 10-Q · filed 2026-08-06 | $10.44M 10-Q · filed 2026-08-06 | $8.31M derived: sum of 3 quarters · filed 2026-08-06 | $8.31M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$2.31M 10-Q · filed 2026-05-12 | -$4.43M derived: sum of 2 quarters · filed 2026-05-12 | -$4.43M derived: sum of 3 quarters · filed 2026-05-12 | -$4.43M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.13M derived: sum of 2 quarters · filed 2026-03-05 | -$2.13M derived: sum of 3 quarters · filed 2026-03-05 | -$2.13M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-10 | -$2.00K 10-K · filed 2024-03-07 | ||||
| 2022-12-31 | -$225.00K 10-K · filed 2024-03-07 | |||||
| 2019-06-30 | -$234.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$271.00K 10-Q · filed 2019-08-08 | ||||
| 2019-04-30 | $372.00K 10-K · filed 2021-03-11 | |||||
| 2019-03-31 | -$37.00K 10-Q · filed 2019-05-09 | |||||
| 2018-06-30 | -$459.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$351.00K 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | $108.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |